Show simple item record

dc.contributor.advisorMartin, Paul T.
dc.creatorCrowe, Kelly E.
dc.date.accessioned2018-03-30T19:56:14Z
dc.date.available2018-03-30T19:56:14Z
dc.date.issued2018-03
dc.identifier.citationCrowe, K. E., Shao, G., Flanigan, K. M., & Martin, P. T. (2016). N-terminal α Dystroglycan (αDG-N): A Potential Serum Biomarker for Duchenne Muscular Dystrophy. Journal of Neuromuscular Diseases, 3(2), 247–260. http://doi.org/10.3233/JND-150127en_US
dc.identifier.urihttp://hdl.handle.net/1811/82219
dc.descriptionBiological Sciences: 2nd Place (The Ohio State University Edward F. Hayes Graduate Research Forum)en_US
dc.description.abstractBackground: Duchenne Muscular Dystrophy (DMD) is a severe, progressive, neuromuscular disorder of childhood. While a number of serum factors have been identified as potential biomarkers of DMD, none, as yet, are proteins within the dystrophin-associated glycoprotein (DAG) complex. Objectives: We have developed an immobilized serum ELISA assay to measure the expression of a constitutively cleaved and secreted component of the DAG complex, the N-terminal domain of α dystroglycan (αDG-N), and assayed relative expression in serum from muscular dystrophy patients and normal controls. Methods: ELISAs of immobilized patient or mouse serum and Western blots were used to assess αDG-N expression. Results: Immobilization of diluted serum on ELISA plates was important for this assay, as methods to measure serum αDG-N in solution were less robust. αDG-N ELISA signals were significantly reduced in DMD serum (27±3% decrease, n=9, p<0.001) relative to serum from otherwise normal controls (n=38), and calculated serum αDG-N DMD concentrations were reduced in DMD relative to normal (p<0.01) and Becker Muscular Dystrophy (n=11, p<0.05) patient serum. By contrast, ELISA signals from patients with Inclusion Body Myositis were not different than normal (4±3% decrease, n=8, p=0.99). αDG-N serum signals were also significantly reduced in utrophin-deficient mdx mice as compared to mdx and wild type mice. Conclusions: Our results are the first demonstration of a component of the DAG complex as a potential serum biomarker in DMD. Such a serum measure could be further developed as a tool to help reflect overall muscle DAG complex expression or stability.en_US
dc.language.isoen_USen_US
dc.publisherIOS Pressen_US
dc.relation.ispartofseries2018 Edward F. Hayes Graduate Research Forum. 32nden_US
dc.subjectDystroglycanen_US
dc.subjectBiomarkeren_US
dc.subjectDystrophinen_US
dc.subjectMuscular Dystrophyen_US
dc.subjectUtrophinen_US
dc.titleN-terminal α Dystroglycan (αDG-N): A Potential Serum Biomarker for Duchenne Muscular Dystrophyen_US
dc.typeArticleen_US
dc.description.embargoNo embargoen_US


Files in this item

Thumbnail

Items in Knowledge Bank are protected by copyright, with all rights reserved, unless otherwise indicated.

This item appears in the following Collection(s)

Show simple item record